From the Journals

Breast cancer care delayed when patients have high deductibles


 

FROM JOURNAL OF CLINICAL ONCOLOGY

High-deductible health insurance plans may be bad for women’s health, suggest results of a new study.

An analysis of data on women without evidence of breast cancer who were covered for at least 1 year in a low annual deductible plan and then switched by their employers to high annual deductible plans showed that when women were forced to shell out substantially more money before their insurance kicked in, they were significantly more likely to have delays in diagnostic breast imaging, breast biopsy, and initiation of chemotherapy.

“Such delays might lead to adverse long-term breast cancer outcomes. Policymakers, health insurers, and employers should consider designing or incentivizing health insurance benefits that facilitate transitions through key steps along the cancer care pathway,” wrote J. Frank Wharam, MB, and colleagues at Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston. The report was published in Journal of Clinical Oncology.

Pages

Recommended Reading

Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
MDedge Hematology and Oncology
AHA: Heart health helps optimize breast cancer outcomes
MDedge Hematology and Oncology
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
MDedge Hematology and Oncology
Cyclophosphamide extends PFS in elderly HER2+ breast cancer patients
MDedge Hematology and Oncology
Exercise during chemotherapy may yield long-term physical benefits
MDedge Hematology and Oncology
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
MDedge Hematology and Oncology
Measurement of physical activity and sedentary behavior in breast cancer survivors
MDedge Hematology and Oncology
Breast cancer deaths projected for 2018
MDedge Hematology and Oncology
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology